<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Alzheimers Res Ther</journal-id><journal-id journal-id-type="iso-abbrev">Alzheimers Res Ther</journal-id><journal-title-group><journal-title>Alzheimer's Research &#x00026; Therapy</journal-title></journal-title-group><issn pub-type="epub">1758-9193</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">26244059</article-id><article-id pub-id-type="pmc">4523931</article-id><article-id pub-id-type="publisher-id">137</article-id><article-id pub-id-type="doi">10.1186/s13195-015-0137-y</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>Modulation of A&#x003b2;42 in vivo by &#x003b3;-secretase modulator in primates and humans</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Ling</surname><given-names>I-Fang</given-names></name><address><email>ifling@ucsd.edu</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Golde</surname><given-names>Todd E.</given-names></name><address><email>tgolde@mbi.ufl.edu</email></address><xref ref-type="aff" rid="Aff2"/></contrib><contrib contrib-type="author"><name><surname>Galasko</surname><given-names>Douglas R.</given-names></name><address><email>dgalasko@ucsd.edu</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Koo</surname><given-names>Edward H.</given-names></name><address><email>edkoo@ucsd.edu</email></address><xref ref-type="aff" rid="Aff1"/><xref ref-type="aff" rid="Aff3"/></contrib><aff id="Aff1"><label/>Department of Neurosciences, University of California, La Jolla, San Diego, CA USA </aff><aff id="Aff2"><label/>Department of Neuroscience, University of Florida, College of Medicine, Gainesville, FL USA </aff><aff id="Aff3"><label/>Departments of Medicine and Physiology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore </aff></contrib-group><pub-date pub-type="epub"><day>5</day><month>8</month><year>2015</year></pub-date><pub-date pub-type="pmc-release"><day>5</day><month>8</month><year>2015</year></pub-date><pub-date pub-type="collection"><year>2015</year></pub-date><volume>7</volume><issue>1</issue><elocation-id>55</elocation-id><history><date date-type="received"><day>17</day><month>4</month><year>2015</year></date><date date-type="accepted"><day>2</day><month>7</month><year>2015</year></date></history><permissions><copyright-statement>&#x000a9; Ling et al. 2015</copyright-statement><license license-type="open-access"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0">http://creativecommons.org/licenses/by/4.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><abstract id="Abs1"><sec><title>Introduction</title><p>Ibuprofen is one of the nonsteroidal anti-inflammatory drugs that have been shown to selectively lower pathogenic amyloid beta-peptide (A&#x003b2;)42 without impairing overall &#x003b3;-secretase activity in vitro. This &#x003b3;-secretase modulator (GSM) activity has been hypothesized to contribute to the reduction in risk of developing Alzheimer&#x02019;s disease in chronic users of nonsteroidal anti-inflammatory drugs. However, it is unclear whether ibuprofen, within therapeutic dosing range, demonstrates GSM activity in humans. In this study, we evaluated the effects of ibuprofen and a second-generation GSM, GSM-1, on A&#x003b2; levels in cerebrospinal fluid and plasma of young nonhuman primates and humans.</p></sec><sec><title>Methods</title><p>Five to seven conscious cynomolgus monkeys (<italic>Macaca fascicularis</italic>) were nontreated or treated with 30 mg/kg GSM-1 or 50 or 100 mg/kg ibuprofen and the plasma and cerebrospinal fluid were sampled at &#x02212;8, 0 (baseline or right before treatment), 2, 4, 6, 8, 12, and 24 h postdosing. In addition, sixteen healthy human subjects were randomly assigned to receive either placebo or 800 mg ibuprofen given by intravenous administration and plasma were collected at 0 (before drug infusion), 0.5, 1, 2, 4, 6, 8, 10, and 24 h after dosing.</p></sec><sec><title>Results</title><p>A single dose of GSM-1 (30 mg/kg) decreased the ratio of A&#x003b2;42 to A&#x003b2;40 to 60 % in plasma and the ratio of A&#x003b2;42 to total A&#x003b2; to 65 % in cerebrospinal fluid from baseline to postdosing in monkeys. However, no significant changes were detected following ibuprofen treatment at 100 mg/kg. Consistent with the results from nonhuman primates, ibuprofen did not alter plasma A&#x003b2; levels in human volunteers after a single 800 mg dose.</p></sec><sec><title>Conclusions</title><p>GSM-1 exerted potent lowering of the ratio of A&#x003b2;42 to A&#x003b2;40 in nonhuman primates but the hypothesized GSM activity of ibuprofen could not be demonstrated in nonhuman primates and humans after acute dosing.</p></sec></abstract><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; The Author(s) 2015</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1" sec-type="introduction"><title>Introduction</title><p>Alzheimer&#x02019;s disease (AD) is the most common age-associated neurodegenerative disease and is accompanied by hippocampal and brain atrophy and is manifested clinically with memory and cognitive impairments [<xref ref-type="bibr" rid="CR1">1</xref>]. Pathologically, AD is characterized by deposition of extracellular amyloid beta-peptide (A&#x003b2;) in senile plaques, intracellular neurofibrillary tangles, and loss of synapses and neurons [<xref ref-type="bibr" rid="CR2">2</xref>]. The cause of AD is still unclear. Much research focuses on the amyloid cascade hypothesis, which states that aggregated forms of A&#x003b2; initiate a cascade of events that result in the full neurodegenerative features of AD [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR4">4</xref>]. A&#x003b2; is derived by sequential proteolysis of the amyloid precursor protein (APP) by &#x003b2;- and &#x003b3;-secretases to generate peptides of 36&#x02013;42 amino acids in length [<xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR6">6</xref>]. The longer but minor species, A&#x003b2;42, is widely believed to represent a more pathogenic species as it aggregates faster than the shorter A&#x003b2;40 species and demonstrates toxicity in vitro and in vivo [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR8">8</xref>]. Mutations in <italic>PSEN1</italic>, <italic>PSEN2</italic> and <italic>APP</italic> genes, causing early onset familial AD (FAD) have been shown to alter A&#x003b2; production, with the majority of <italic>PSEN</italic> mutations elevating the ratio of A&#x003b2;42/A&#x003b2;40 [<xref ref-type="bibr" rid="CR9">9</xref>&#x02013;<xref ref-type="bibr" rid="CR11">11</xref>]. At present there is no effective treatment for AD and current medications are mildly effective in treating the symptoms but do not show disease-modifying effects [<xref ref-type="bibr" rid="CR12">12</xref>].</p><p>Because &#x003b3;-secretase cleavage is the final step in A&#x003b2; production, inhibition or modulation of &#x003b3;-secretase serves a logical therapeutic target for AD. In contrast to the nondiscriminant inhibition of &#x003b3;-secretase inhibitors (GSI), &#x003b3;-secretase modulators (GSMs) are thought to be intrinsically safer as they target the pathogenic A&#x003b2;42 species without inhibiting normal APP processing or cleavage of other &#x003b3;-secretase substrates, such as Notch and ErbB4 [<xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR14">14</xref>]. GSMs increase the processivity of &#x003b3;-secretase to promote further cleavage of A&#x003b2;42 peptides, resulting in decreased A&#x003b2;42 and increased shorter species, such as A&#x003b2;37 and A&#x003b2;38, thereby reducing the ratio of A&#x003b2;42/A&#x003b2;40 [<xref ref-type="bibr" rid="CR15">15</xref>]. GSM activity was first observed in a subset of nonsteroidal anti-inflammatory drugs (NSAIDs), such as ibuprofen, indomethacin and sulindac sulfide, when used at high doses, an observation that might explain the epidemiological link between NSAID use and AD risk reduction [<xref ref-type="bibr" rid="CR16">16</xref>&#x02013;<xref ref-type="bibr" rid="CR18">18</xref>]. Since the initial description of the GSM activity of certain NSAIDs, numerous GSMs with more potent activity have been reported [<xref ref-type="bibr" rid="CR19">19</xref>&#x02013;<xref ref-type="bibr" rid="CR21">21</xref>]. However, it is unclear whether NSAIDs exhibit GSM activity in humans as this has never been tested. Thus, if such compounds were to be used prophylactically as potential preventive treatment, it is important to establish whether the NSAIDs with GSM activity in vitro behave similarly in vivo<italic>.</italic></p><p>Although GSMs have shown efficacy in preclinical models, tarenflurbil, the <italic>R</italic>-enantiomer of flurbiprofen was shown not to be effective in a late-phase human clinical trial possibly due to lack of potency or brain penetration [<xref ref-type="bibr" rid="CR22">22</xref>, <xref ref-type="bibr" rid="CR23">23</xref>]. Because newer GSMs have not yet demonstrated clinical efficacy, we chose to examine whether ibuprofen has GSM activity in nonhuman primates and humans following acute dosing. Ibuprofen is one of the NSAIDs with GSM activity in preclinical studies and chronic use has been linked to a reduction in AD risk [<xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR18">18</xref>, <xref ref-type="bibr" rid="CR24">24</xref>&#x02013;<xref ref-type="bibr" rid="CR27">27</xref>]. However, it is unclear whether the drug, within the therapeutic dosing range, can modulate A&#x003b2;42 levels in vivo in humans. Consequently, in this study, we evaluated the effects of ibuprofen and a potent second-generation GSM, GSM-1 [<xref ref-type="bibr" rid="CR28">28</xref>], on plasma and cerebrospinal fluid (CSF) A&#x003b2; levels in young cynomolgus monkeys, a model that has been used to examine GSI efficacy in vivo [<xref ref-type="bibr" rid="CR29">29</xref>]. In addition, we took advantage of the recent US Food and Drug Administration (FDA) approval of an intravenous (IV) formulation of ibuprofen (Caldolor) to examine the effect of a single high dose of ibuprofen on plasma A&#x003b2; levels in humans. In contrast to GSM-1, we failed to detect any GSM activity of ibuprofen on plasma and CSF A&#x003b2;42 levels in nonhuman primates or plasma A&#x003b2;42 levels in humans.</p></sec><sec id="Sec2" sec-type="materials|methods"><title>Methods</title><sec id="Sec3"><title>Reagents and antibodies</title><p>All compounds and reagents were from commercial venders as follows: IV-ibuprofen (Caldolor; Cumberland Pharmaceuticals, Nashville, TN, USA); ibuprofen (Nurofen; Ibuprofen B.P. 200 mg; Reckitt Benckiser, Slough, UK); A&#x003b2;38 and A&#x003b2;40 enzyme-linked immunosorbent assay (ELISA) kits (IBL-International, Toronto, Canada); INNOTEST A&#x003b2;42 kit (Innogenetics, Alpharetta, GA, USA); MSD A&#x003b2; Triplex kit (Meso Scale Discovery, Gaithersburg, MD, USA); and Ibuprofen ELISA kit (Neogen, Lexington, KY, USA). GSM-1 was custom synthesized at Mayo Clinic (Jacksonville, FL, USA) by following published procedures [<xref ref-type="bibr" rid="CR30">30</xref>] and verified by a combination of thin-layer chromatography (TLC), nuclear magnetic resonance (NMR) and electrospray ionization (ESI) analyses. The in vitro efficacy has been confirmed in previous publications [<xref ref-type="bibr" rid="CR31">31</xref>, <xref ref-type="bibr" rid="CR32">32</xref>]. Antibodies included Ab9 (Mayo Clinic), 82E1 (IBL-International), 4G8-biotin (Covance, Princeton, NJ, USA), streptavidin-HRP (Jackson ImmunoResearch, West Grove, PA, USA), A&#x003b2;42 specific antibodies MM26-2.1.3 (Mayo Clinic), and 6E10-HRP (Covance).</p></sec><sec id="Sec4"><title>Cell culture</title><p>Chinese hamster ovary (CHO) cells stably expressing wild-type APP751 (APP-WT) and CHO cells stably expressing APP751 with the Val717Phe familial AD mutation (APP-V717F) were maintained in Dulbecco&#x02019;s modified Eagle&#x02019;s medium (DMEM) supplemented with 10 % fetal bovine serum, 50 U/ml penicillin and 50 &#x003bc;g/ml streptomycin at 37 &#x000b0;C in a humidified 5 % CO<sub>2</sub>/95 % air atmosphere.</p></sec><sec id="Sec5"><title>Drug treatments in cynomolgus monkeys</title><p>All procedures related to the use of animals were approved by the Institutional Animal Care and Use Committee (IACUC) of Maccine Pte Ltd (Singapore). A total of seven, non-naive female cynomolgus macaques (<italic>Macaca fascicularis</italic>), aged 2.5&#x02013;5 years, were studied. A cisterna magna catheter and port system was surgically implanted in each monkey [<xref ref-type="bibr" rid="CR33">33</xref>] and animals were allowed recover for 2&#x02013;3 weeks prior to treatment. Following recovery, the animals were studied sequentially over the subsequent weeks under different conditions, which were changed on a weekly basis. In the first week, no treatment was given and the CSF and plasma were sampled from the monkeys at &#x02212;8, 0 (baseline), 2, 4, 6, 8, 12, and 24 h. In the following weeks, the animals were treated with GSM-1 (30 mg/kg), IV-ibuprofen (50 mg/kg), or ibuprofen (100 mg/kg) with a 7-day rest/washout period between each treatment condition.</p><p>IV-ibuprofen was diluted with saline to 4 mg/ml and IV infused to achieve the dose of 50 mg/kg. Ibuprofen was supplied as a 200 mg caplet. Each animal was provided with one caplet of 200 mg ibuprofen and one capsule containing the weighed amount of the grounded ibuprofen caplet to meet the required dose of 100 mg/kg. Ibuprofen was administered by using an appropriate catheter tube. GSM-1 was prepared by dissolving in 5 % (v/v) ethanol, 10 % (v/v) solutol HS-15 and 85 % (v/v) Milli-Q water on the day of dosing. Oral administration of GSM-1 was achieved by gavage.</p></sec><sec id="Sec6"><title>Human study</title><p>The study was approved by Human Research Protections Program and the Institutional Review Board at the University of California, San Diego, and carried out at the Shiley-Marcos Alzheimer&#x02019;s Disease Research Center and Clinical Translational Research Institute at the University of California, San Diego. Subjects were recruited and screened. Exclusion criteria included contraindication to blood draw, chronic major psychiatric disorders, history of peptic ulcer or upper gastrointestinal bleed, significant medical illness, hypersensitivity/allergy to ibuprofen or other NSAID drugs, and regular use of aspirin or NSAIDs. All subjects provided written informed consent to participate in this study.</p><p>Sixteen eligible healthy subjects, 6 men and 10 women from 21 to 35 years of age, participated in this study. After an overnight fast, the subjects were randomized to receive 800 mg IV-ibuprofen or placebo. Plasma was sampled at time 0 (before drug infusion), 0.5, 1, 2, 4, 6, 8, 10, and 24 h after dosing.</p></sec><sec id="Sec7"><title>Sandwich ELISA</title><p>Quantification of total A&#x003b2; and A&#x003b2;42 peptides was carried out with sensitive ELISAs. For total A&#x003b2;, Ab9 antibody (20 &#x003bc;g/ml), which recognizes A&#x003b2;1&#x02013;16, was used as capture and 4G8-biotin (20 &#x003bc;g/ml) and strepavidin-HRP were used as reporter. A&#x003b2;42 was measured by the A&#x003b2;42 end-specific MM26-2.1.3 antibody (50 &#x003bc;g/ml) [<xref ref-type="bibr" rid="CR34">34</xref>] as capture antibody and 6E10-HRP (1 &#x003bc;g/ml) as reporter. 4G8 and 6E10 recognize A&#x003b2;17&#x02013;24 and A&#x003b2;1&#x02013;16, respectively. CSF A&#x003b2;38 was measured by a commercial A&#x003b2;38 ELISA kit (IBL), following manufacturer&#x02019;s instructions. Plasma A&#x003b2; species were measured by either A&#x003b2;40 (IBL), A&#x003b2;42 (Innotest) or A&#x003b2; Triplex (MSD) kit, following manufacturer&#x02019;s instructions. Plasma levels of ibuprofen were measured by a commercial ELISA system (Neogen), following manufacturer&#x02019;s instructions.</p></sec><sec id="Sec8"><title>Statistical analysis</title><p>The effects of drugs on CSF and plasma A&#x003b2; ratios in monkeys and plasma A&#x003b2; ratios in humans were analyzed by a two-way analysis of variance with a post hoc Bonferroni posttest (GraphPad Prism, La Jolla, CA, USA).</p></sec></sec><sec id="Sec9" sec-type="results"><title>Results</title><sec id="Sec10"><title>GSM activity of ibuprofen and GSM-1 in vitro</title><p>This study was designed to test the physiological activity of two GSMs in primates following acute dosing: a NSAID ibuprofen and GSM-1, an experimental compound. Before evaluating the effects in vivo, we first confirmed their GSM activity in vitro. CHO cells stably expressing APP-WT or APP-V717F were incubated with ibuprofen or GSM-1 for 24 h. Conditioned media were collected and A&#x003b2;42 and total A&#x003b2; levels were quantified by ELISA analyses. Both ibuprofen and GSM-1 significantly reduced the ratio of A&#x003b2;42 to total A&#x003b2; in a dose-dependent manner, indicating the modulation of &#x003b3;-secretase activity (<italic>p</italic> &#x0003c; 0.001; Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>). As expected, GSM-1 showed greater potency with 50 % reduction at 0.2 &#x003bc;M whereas ibuprofen required 250&#x02013;500 &#x003bc;M to reach similar level of A&#x003b2;42 changes (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>).<fig id="Fig1"><label>Fig. 1</label><caption><p>The efficacy of ibuprofen and GSM-1 on selectively decreasing A&#x003b2;42 in vitro. Total amyloid beta-peptide (A&#x003b2;) and A&#x003b2;42 levels in conditioned media from cells stably expressing wild-type APP751 (APP-WT) and cells stably expressing APP751 with the Val717Phe familial AD mutation (APP-V717F) after drug incubation for 24 h were evaluated by enzyme-linked immunosorbent assays (ELISAs) and ratios were compared. All experiments were repeated at least twice. Results are presented as mean &#x000b1; range. <italic>GSM</italic> gamma-secretase modulator</p></caption><graphic xlink:href="13195_2015_137_Fig1_HTML" id="MO1"/></fig></p></sec><sec id="Sec11"><title>Effects of ibuprofen and GSM-1 on A&#x003b2; in cynomolgus monkeys</title><p>Seven young cynomolgus monkeys were first studied without drug treatment to determine the basal A&#x003b2; levels over a 32-hour period. The CSF and plasma samples were collected at &#x02212;8, 0 (baseline), 2, 4, 6, 8, 12 and 24 h after baseline. A&#x003b2;42, A&#x003b2;38 and total A&#x003b2; levels in CSF samples were measured. During the observation period, there was variation in A&#x003b2; levels in untreated animals (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2a&#x02013;c</xref>) without a clear diurnal pattern, consistent with the reports from catheter studies in humans [<xref ref-type="bibr" rid="CR35">35</xref>]. Animals were then treated with drugs in subsequent weeks sequentially. Between each treatment, all animals were rested for 1 week to allow drug washout. In drug-treated animals, GSM-1 significantly reduced A&#x003b2;42 and increased A&#x003b2;38 levels (both <italic>p</italic> &#x0003c; 0.001), but did not change total A&#x003b2; levels (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2a&#x02013;c</xref>). Maximal reduction of ~32 % in A&#x003b2;42 levels (from 267.1 &#x000b1; 60.0 (mean &#x000b1; SD) to 183.5 &#x000b1; 96.1 pg/mL) was noted at 12 h postdosing (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2b</xref>). Meanwhile, A&#x003b2;38 levels increased ~90 % maximally (from 1033.3 &#x000b1; 300.0 to 1954.8 &#x000b1; 698.6 pg/mL; Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2c</xref>) at 8 h postdosing. GSM-1 decreased the ratio of A&#x003b2;42 to total A&#x003b2; up to 35 % at 12 h after administration (<italic>p</italic> &#x0003c; 0.001; Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2d</xref>) and increased the ratio of A&#x003b2;38 to total A&#x003b2; maximally by 70 % after 8 h (<italic>p</italic> &#x0003c; 0.05; Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2e</xref>). In light of the CSF results, the effects of GSM-1 were mirrored in plasma. Specifically, the ratio of A&#x003b2;42/A&#x003b2;40 in plasma was markedly decreased (<italic>p</italic> &#x0003c; 0.001; Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2f</xref>). This was evident as early as 2 h following drug administration and plateaued starting at 4 h. GSM-1 reduced the ratio of A&#x003b2;42/A&#x003b2;40 up to 40 % at 6 h after dosing. These changes in plasma A&#x003b2; were more rapid than were observed in CSF, where the maximum reduction was delayed to 8&#x02013;12 h, but the magnitude of reduction was similar (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2d,f</xref>).<fig id="Fig2"><label>Fig. 2</label><caption><p>The effects of ibuprofen and GSM-1 on CSF and plasma A&#x003b2; levels in cynomolgus monkeys. Cerebrospinal fluid (CSF) and plasma samples were collected at indicated time points and amyloid beta-peptide (A&#x003b2;) levels were measured. Levels of total A&#x003b2; (<bold>a</bold>), A&#x003b2;42 (<bold>b</bold>) and A&#x003b2;38 (<bold>c</bold>) were compared in CSF samples. Ratios of A&#x003b2;42 to total A&#x003b2; (<bold>d</bold>) and A&#x003b2;38 to total A&#x003b2; (<bold>e</bold>) were compared in CSF samples and ratios of A&#x003b2;42/A&#x003b2;40 were compared in plasma samples (<bold>f</bold>). The levels and ratios were normalized to baseline (time 0 or before drug dosing) and shown as percentages of baseline. Seven monkeys were used in the no-treatment group. However, the catheters in two animals did not maintain patency during the study period. Therefore, fewer animals received the single dose of GSM-1 (n = 6) or ibuprofen (n = 5). Results are presented as mean &#x000b1; SEM; *<italic>p</italic> &#x0003c; 0.05, **<italic>p</italic> &#x0003c; 0.001. <italic>GSM</italic> gamma-secretase modulator</p></caption><graphic xlink:href="13195_2015_137_Fig2_HTML" id="MO2"/></fig></p><p>In contrast to GSM-1, no changes could be detected in any of the A&#x003b2; levels or ratios in either CSF or plasma following ibuprofen administration at either 50 mg/kg (data not shown) or 100 mg/kg (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>). Specifically, there was no reduction in the ratio of A&#x003b2;42 to total A&#x003b2; nor an increase in the ratio of A&#x003b2;38 to total A&#x003b2; in CSF and no change in the ratio of A&#x003b2;42/A&#x003b2;40 in plasma after ibuprofen treatment (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2d&#x02013;f</xref>). In sum, these results showed that a single-dose administration of GSM-1 potently modulated A&#x003b2; production. In contrast, a single high dose of ibuprofen did not result in any detectable changes in A&#x003b2; production in monkeys that would be consistent with &#x003b3;-secretase modulation.</p></sec><sec id="Sec12"><title>Effects of ibuprofen on A&#x003b2; in humans</title><p>We next evaluated the effects of IV-ibuprofen or placebo on plasma A&#x003b2; levels in humans. Nineteen subjects were screened and sixteen eligible healthy subjects were enrolled in the study (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>). With eight subjects in each group, we anticipated being able to detect changes of 20 % or more in plasma A&#x003b2;42 levels if ibuprofen showed GSM activity based on a GSI study [<xref ref-type="bibr" rid="CR36">36</xref>]. Subjects were randomly assigned to receive either placebo or 800 mg IV-ibuprofen. The latter dose reflects the highest FDA-approved single human dose given four times daily (total of 3.2 g per day). Given the plasma results of GSM-1 treatment in monkeys, blood samples were drawn at baseline (before drug infusion), 0.5, 1, 2, 4, 6, 8, 10, and 24 h after dosing. During the study period, no adverse events were observed in subjects. The levels of A&#x003b2;38, A&#x003b2;40 and A&#x003b2;42 in plasma samples were measured. Subject demographics and baseline A&#x003b2; levels are summarized in Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>. Baseline plasma levels of A&#x003b2; peptides showed substantial variability between subjects. The A&#x003b2;42 levels ranged from 23.2 to 1524.5 pg/mL, and the A&#x003b2;40 levels ranged from 229.2 to 1392.2 pg/ml. When the baseline ratios of A&#x003b2;42/A&#x003b2;40 were compared, most subjects reflected the generally minor contribution of A&#x003b2;42 to A&#x003b2;40 with ratios of approximately 0.1, but several subjects (#11, 14 and 15) showed relatively higher A&#x003b2;42 levels with ratios of approximately 1 (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4a</xref>). In contrast, the ratios of A&#x003b2;42/A&#x003b2;38 ranged from 0.5 to 1 with the majority around 1 (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4b</xref>). Comparing either the ratios of A&#x003b2;42/A&#x003b2;40 and A&#x003b2;38/A&#x003b2;40 in plasma in subjects who received ibuprofen versus placebo, no changes could be detected after drug treatment (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4c,d</xref>). These results demonstrated that a single dose of 800 mg ibuprofen did not result in any acute changes in A&#x003b2; production in humans, a finding consistent with the observations from nonhuman primates.<fig id="Fig3"><label>Fig. 3</label><caption><p>Participation flow chart for the human study. Nineteen subjects were recruited and screened. Three subjects were excluded from the study: two due to high blood creatinine level and invisible veins, respectively, and one declined to participate after screening. Samples from two subjects were excluded for analysis due to technical reasons. <italic>IV</italic> intravenous</p></caption><graphic xlink:href="13195_2015_137_Fig3_HTML" id="MO3"/></fig><table-wrap id="Tab1"><label>Table 1</label><caption><p>Demographic data and subject characteristics at baseline (n = 7 for each group)</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th>Placebo</th><th>Ibuprofen</th></tr></thead><tbody><tr><td>Age (mean &#x000b1; SD)</td><td>27.4 &#x000b1; 5.5</td><td>25.7 &#x000b1; 3.6</td></tr><tr><td>Sex</td><td>3 females, 4 males</td><td>5 females, 2 males</td></tr><tr><td>A&#x003b2;38 Level (pg/mL)</td><td>199.1 &#x000b1; 276.0</td><td>344.6 &#x000b1; 603.5</td></tr><tr><td>(mean &#x000b1; SD (lowest; highest))</td><td>(25.7; 746.8)</td><td>(25.6; 1694.4)</td></tr><tr><td>A&#x003b2;40 Level (pg/mL)</td><td>348.2 &#x000b1; 152.8</td><td>468.0 &#x000b1; 409.5</td></tr><tr><td>(mean &#x000b1; SD (lowest; highest))</td><td>(229.2; 659.1)</td><td>(259.9; 1392.2)</td></tr><tr><td>A&#x003b2;42 Level (pg/mL)</td><td>183.8 &#x000b1; 257.6</td><td>295.5 &#x000b1; 547.3</td></tr><tr><td>(mean &#x000b1; SD (lowest; highest))</td><td>(23.2; 681.4)</td><td>(27.5; 1524.5)</td></tr></tbody></table></table-wrap><fig id="Fig4"><label>Fig. 4</label><caption><p>The effect of a single dose of 800 mg IV-ibuprofen on A&#x003b2; levels in humans. Plasma samples were collected at indicated time points and amyloid beta-peptide (A&#x003b2;) levels were analyzed. Ratios of A&#x003b2;42/A&#x003b2;40 (<bold>a</bold>) and A&#x003b2;42/A&#x003b2;38 (<bold>b</bold>) at baseline (before infusion) were compared among subjects. Then ratios of A&#x003b2;42/A&#x003b2;40 (<bold>c</bold>) and A&#x003b2;38/A&#x003b2;40 (<bold>d</bold>) between placebo and ibuprofen groups were compared. Results are presented as mean &#x000b1; SEM</p></caption><graphic xlink:href="13195_2015_137_Fig4_HTML" id="MO4"/></fig></p><p>The negative results in plasma after ibuprofen treatment in both humans and monkeys were unexpected. Although IV administration should have resulted in near complete systemic drug delivery, it is important to confirm adequate drug levels in plasma in humans. Because the half-life of ibuprofen is approximately 2 h in plasma [<xref ref-type="bibr" rid="CR37">37</xref>], drug levels were measured in samples at 0, 1, 2, 4, and 8 h after infusion. For comparison, we also analyzed the monkey CSF and plasma samples at 0, 2, 4, and 8 hours after oral dosing with 100 mg/kg ibuprofen. In humans, the highest plasma levels of ibuprofen were seen at 1 hour, the first time sampled, and returned to baseline levels by 8 h (Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5a</xref>). The maximum average concentration of total ibuprofen (bound and unbound) (C<sub>max total</sub>) was 441.63 &#x000b1; 113.84 (mean &#x000b1; SD) &#x003bc;M (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>). Because ibuprofen has been reported to be ~99 % bound to plasma proteins [<xref ref-type="bibr" rid="CR38">38</xref>], free unbound concentration of ibuprofen was estimated to be approximately 4.4 &#x003bc;M. In monkeys, ibuprofen concentrations were highest at 2 h, again the first sampled time point, after oral administration in all but one animal in both plasma and CSF (Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5b,c</xref>). The C<sub>max total</sub> in CSF was 12.24 &#x003bc;M, which is ~ 1 % of the C<sub>max total</sub> in plasma (1060.33 &#x003bc;M) (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>). Comparing the area under curve from 0 to 8 h, the calculated CSF:plasma ratio was about 0.01 in monkeys after a single dose of 100 mg/kg ibuprofen (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>), consistent with the generally low brain penetration of NSAIDs [<xref ref-type="bibr" rid="CR39">39</xref>, <xref ref-type="bibr" rid="CR40">40</xref>]. Finally, interleukin (IL)-1&#x003b2; and IL-6 levels were assayed from human plasma and, not surprisingly, there were no differences between control and ibuprofen-treated groups (data not shown) because there is no documented suppression of these inflammatory markers by ibuprofen in healthy individuals [<xref ref-type="bibr" rid="CR41">41</xref>].<fig id="Fig5"><label>Fig. 5</label><caption><p>Ibuprofen concentrations in human and monkey samples after dosing. Ibuprofen concentrations were evaluated by ELISAs. <bold>a</bold> Plasma samples from seven human subjects who received 800 mg of IV-ibuprofen were analyzed. <bold>b</bold> Plasma and <bold>c</bold> cerebrospinal fluid (CSF) samples from five monkeys treated with 100 mg/kg ibuprofen were evaluated</p></caption><graphic xlink:href="13195_2015_137_Fig5_HTML" id="MO5"/></fig><table-wrap id="Tab2"><label>Table 2</label><caption><p>Pharmacokinetics of ibuprofen in humans (800 mg) and monkeys (100 mg/kg) after acute treatment</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2"/><th>Human (n = 7)</th><th colspan="2">Monkey (n = 5)</th></tr><tr><th>Plasma</th><th>CSF</th><th>Plasma</th></tr></thead><tbody><tr><td>C<sub>max total</sub> (&#x003bc;M)<sup>a</sup>
</td><td>441.63 &#x000b1; 113.84</td><td>12.24 &#x000b1; 8.18</td><td>1060.33 &#x000b1; 565.25</td></tr><tr><td>AUC<sub>0&#x02013;8h</sub> (&#x003bc;M*h)</td><td>831.44 &#x000b1; 155.92</td><td>36.36 &#x000b1; 11.75</td><td>3744.8 &#x000b1; 924.16</td></tr><tr><td>CSF:plasma ratio</td><td/><td colspan="2">0.01 &#x000b1; 0.004</td></tr></tbody></table><table-wrap-foot><p>
<sup>a</sup>Total concentration (bound and unbound). <italic>AUC</italic>
<sub><italic>0&#x02013;8h</italic></sub> area under the curve from 0 to 8 h, <italic>C</italic>
<sub><italic>max</italic></sub> maximum average concentration, <italic>CSF</italic> cerebrospinal fluid</p></table-wrap-foot></table-wrap></p></sec></sec><sec id="Sec13" sec-type="discussion"><title>Discussion</title><p>In this study, we sought to test whether ibuprofen demonstrates any GSM activity in plasma and CSF in nonhuman primates and humans following acute dosing. Contrary to previous in vitro studies, a single high dose of ibuprofen did not modulate A&#x003b2; levels as would be predicted if the compound has &#x003b3;-secretase modulating activity in vivo at the dose given acutely. At a high dose, but within the therapeutic dosing range (i.e., 800 mg IV-ibuprofen), there were no changes in A&#x003b2; levels in human plasma. Even higher doses in nonhuman primates, 100 mg/kg, failed to demonstrate A&#x003b2;42 reduction in CSF or plasma. In contrast, a second-generation GSM, GSM-1, demonstrated potent changes in A&#x003b2;42 and A&#x003b2;38 levels in CSF and plasma in monkeys indicative of &#x003b3;-secretase modulation. These latter findings showed that &#x003b3;-secretase complex can be modulated in primates in a manner consistent with prototypic GSM activity first defined in vitro and in rodents.</p><p>Epidemiological studies have consistently shown that chronic usage of NSAIDs reduced the risk of AD and, further, that the protective effects are linked with the duration of NSAID use [<xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR18">18</xref>, <xref ref-type="bibr" rid="CR42">42</xref>]. A recent study using a Veterans Administration database reported that ibuprofen, one of the three most commonly used NSAIDs together with naproxen and indomethacin, had the strongest protective effect against AD when used for more than 5 years [<xref ref-type="bibr" rid="CR18">18</xref>]. However, there was no correlation between NSAIDs that had GSM activity versus those that did not [<xref ref-type="bibr" rid="CR43">43</xref>]. In a 1-year treatment trial of mild to moderate AD individuals, there was no benefit of 400 mg ibuprofen given twice daily, but a sub-analysis of apoE4 individuals suggested slowing in cognitive decline [<xref ref-type="bibr" rid="CR44">44</xref>]. Other treatment trials with NSAIDs have either been negative or demonstrated equivocal benefit [<xref ref-type="bibr" rid="CR45">45</xref>&#x02013;<xref ref-type="bibr" rid="CR48">48</xref>].</p><p>Unresolved in all the observational studies are the mechanisms by which NSAID use may lower the risk for developing AD, if this happens [<xref ref-type="bibr" rid="CR49">49</xref>]. A number of mechanisms have been proposed but none have been rigorously tested [<xref ref-type="bibr" rid="CR50">50</xref>]. In this study, we tested whether ibuprofen may act as a GSM and reduce production of the pathogenic A&#x003b2;42 peptides through this mechanism. In preclinical studies, subacute treatment with 50 mg/kg ibuprofen for 3 days significantly reduced A&#x003b2;42 but not A&#x003b2;40 levels in the Tg2576 line of APP transgenic mice [<xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR51">51</xref>]. Chronic treatment with ibuprofen decreased amyloid load in the brain accompanied by reduction in all A&#x003b2; species, and rescued memory deficits in the same APP transgenic mouse line [<xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR24">24</xref>, <xref ref-type="bibr" rid="CR26">26</xref>, <xref ref-type="bibr" rid="CR27">27</xref>], but the mechanisms for these effects were not established. Furthermore, we are not aware of a study in rodents that examined the changes in A&#x003b2; peptides after acute treatment with ibuprofen to demonstrate GSM activity, nor has the GSM activity of ibuprofen been examined directly in primates. Results from this study showed that, contrary to expectations, a single high dose of ibuprofen did not reduce A&#x003b2;42 levels in monkeys or humans (Figs.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref> and <xref rid="Fig4" ref-type="fig">4</xref>). The maximum average concentrations of total ibuprofen detected from plasma in monkeys and human subjects were 1060.33 &#x003bc;M and 441.63 &#x003bc;M, respectively (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>). Although the assay used in this study may be less quantitative than other methods, such as liquid chromatography-tandem mass spectrometry, the drug levels were within the range of published reports [<xref ref-type="bibr" rid="CR37">37</xref>]. Further, we did not measure free versus bound concentration of the drug. However, because ibuprofen is about 99 % bound to plasma proteins in humans [<xref ref-type="bibr" rid="CR38">38</xref>], the estimated unbound concentration of ibuprofen was ~4.4 &#x003bc;M. In mice treated with 50 mg/kg ibuprofen daily for 3 days and reported to demonstrate GSM activity, the average plasma drug concentration was 43 &#x003bc;M, 2 h after the last dose [<xref ref-type="bibr" rid="CR51">51</xref>]. Because the unbound fraction of ibuprofen in rodents has been reported to be ~5.5 % [<xref ref-type="bibr" rid="CR52">52</xref>], the estimated unbound ibuprofen concentration in that study would be ~2.37 &#x003bc;M, a level that is comparable to what we detected in humans. Consequently, the lack of effect of ibuprofen in humans and monkeys cannot be easily attributable to insufficient drug exposure, at least if treatment for 3 days in mice is comparable to the single acute treatment given in the present study. Another potential explanation for the negative results is that, because of lower efficacy, ibuprofen may require more sustained treatment, as was done in the APP transgenic mouse line. However, in view of the robust effects of GSM-1 in monkeys, this reasoning is perhaps less convincing. Therefore, our results suggested that if subchronic to chronic treatment of ibuprofen were effective in decreasing brain A&#x003b2; levels in primates, it may not be due to direct &#x003b3;-secretase modulation, but possibly acting in combination with other mechanisms, such as lowering pro-inflammatory cytokines to decrease APP expression and A&#x003b2; accumulation, increasing anti-inflammatory cytokines to facilitate A&#x003b2; clearance, or anti-aggregation properties to reduce A&#x003b2; fibril formation [<xref ref-type="bibr" rid="CR50">50</xref>]. Interestingly, in the 5XFAD mice with aggressive early amyloid pathology, 3 months of treatment with ibuprofen resulted in an increase rather than decrease in soluble A&#x003b2; levels and worsening of behavioral performance even in the presence of demonstrated reduction in inflammatory responses. This study in rodents called into question the beneficial effects of anti-inflammatory treatments targeting the cyclooxygenase pathway [<xref ref-type="bibr" rid="CR53">53</xref>]. Taken together, the effects of ibuprofen are complicated. If indeed they are beneficial in preventing AD in humans, the mechanism of risk reduction may occur through multiple pathways that have thus far not been adequately tested in preclinical or clinical settings.</p><p>In stark contrast to ibuprofen, the second-generation GSM-1 significantly decreased A&#x003b2;42 ratios in CSF and plasma in monkeys. GSM-1 is a NSAID-derived carboxylic acid-containing GSM originally developed by Merck by modulating compound structure to reduce lipophilicity [<xref ref-type="bibr" rid="CR19">19</xref>&#x02013;<xref ref-type="bibr" rid="CR21">21</xref>, <xref ref-type="bibr" rid="CR30">30</xref>]. The drug efficacy in transgenic mice was first reported by Page and colleagues where a single dose of GSM-1 given at even 3 mg/kg lowered brain A&#x003b2;42 by 25 % and, at 30 mg/kg, brain A&#x003b2;42 was reduced by 70 % in APP transgenic mice. As would be expected, A&#x003b2;38 levels were concomitantly increased [<xref ref-type="bibr" rid="CR28">28</xref>]. Consistent with these rodent studies, we observed a 40 % reduction in ratio of A&#x003b2;42/A&#x003b2;40 in plasma 4 h after dosing, whereas CSF ratio of A&#x003b2;42 to total A&#x003b2; was decreased by 35 % 12 h after treatment in monkeys (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2d,f</xref>). At the same time, changes in A&#x003b2;38 levels appeared more rapidly and were more sustained (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2e</xref>). While the reciprocal A&#x003b2;42 and A&#x003b2;38 changes are one of the &#x0201c;signatures&#x0201d; of NSAID-based GSMs, it is unclear whether these alterations are mechanistically linked or occur independently. The uncoupling of the two events had been reported in the setting of presenilin 1 (PS1) or PS2 mutations [<xref ref-type="bibr" rid="CR28">28</xref>, <xref ref-type="bibr" rid="CR54">54</xref>]. In addition, a recent study reported that a novel GSM decreased both A&#x003b2;42 and A&#x003b2;38 levels while increasing A&#x003b2;37 and A&#x003b2;39 peptides [<xref ref-type="bibr" rid="CR55">55</xref>]. These results suggested this coupling is not necessarily obligatory.</p><p>As expected, the second generation GSM-1 is much more potent than ibuprofen in vitro with an ED<sub>50</sub> of GSM-1 of approximately 200 nM, compared to 250&#x02013;500 &#x003bc;M for ibuprofen (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>). Although not reported for GSM-1, a GSM with similar structure and comparable in vitro and in vivo GSM activity, GSM-10 h, demonstrated excellent brain penetration in an APP transgenic mouse line (TASTPM) [<xref ref-type="bibr" rid="CR56">56</xref>]. In contrast, as estimated from the CSF to plasma ratio, ibuprofen brain penetration was about 1 % in monkeys (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>), a value consistent with other NSAIDs [<xref ref-type="bibr" rid="CR39">39</xref>, <xref ref-type="bibr" rid="CR40">40</xref>, <xref ref-type="bibr" rid="CR51">51</xref>]. Furthermore, NSAIDs such as fenofibrate and flurbiprofen have been reported to bind to APP, presumably one mechanism of action underlying the NSAID-based GSMs [<xref ref-type="bibr" rid="CR57">57</xref>]. On the other hand, GSM-1, like other second-generation compounds, binds directly to the PS1 N-terminal fragment and through this interaction is believed to alter &#x003b3;-secretase processing in an allosteric manner [<xref ref-type="bibr" rid="CR58">58</xref>&#x02013;<xref ref-type="bibr" rid="CR61">61</xref>]. Whether these differences in binding sites confer different efficacy or mode of action has not been established.</p></sec><sec id="Sec14" sec-type="conclusion"><title>Conclusions</title><p>This study showed that a single high dose of ibuprofen did not result in &#x003b3;-secretase modulating activity in nonhuman primates and humans. It is unclear whether multiple dosing would achieve the desired A&#x003b2;42 reduction as this was not addressed in our study. However, a more potent second-generation compound, GSM-1, selectively decreased plasma and CSF A&#x003b2;42 levels in nonhuman primates in a manner consistent with the GSM class of drugs. This study also reaffirms the utility of using a nonhuman primate model to examine AD-targeted therapeutics in a more physiologically relevant system.</p></sec></body><back><glossary><title>Abbreviations</title><def-list><def-item><term>A&#x003b2;</term><def><p>Amyloid beta-peptide</p></def></def-item><def-item><term>AD</term><def><p>Alzheimer&#x02019;s disease</p></def></def-item><def-item><term>APP</term><def><p>Amyloid precursor protein</p></def></def-item><def-item><term>APP-V717F</term><def><p>APP751 with Val717Phe mutation</p></def></def-item><def-item><term>APP-WT</term><def><p>Wild-type APP751</p></def></def-item><def-item><term>CHO</term><def><p>Chinese hamster ovary</p></def></def-item><def-item><term>C<sub>max</sub></term><def><p>Maximum average concentration</p></def></def-item><def-item><term>CSF</term><def><p>Cerebrospinal fluid</p></def></def-item><def-item><term>DMEM</term><def><p>Dulbecco&#x02019;s modified Eagle&#x02019;s medium</p></def></def-item><def-item><term>ELISA</term><def><p>Enzyme-linked immunosorbent assay</p></def></def-item><def-item><term>ESI</term><def><p>Electrospray ionization</p></def></def-item><def-item><term>FAD</term><def><p>Familial Alzheimer&#x02019;s disease</p></def></def-item><def-item><term>FDA</term><def><p>US Food and Drug Administration</p></def></def-item><def-item><term>GSI</term><def><p>Gamma-secretase inhibitor</p></def></def-item><def-item><term>GSM</term><def><p>Gamma-secretase modulator</p></def></def-item><def-item><term>IL</term><def><p>Interleukin</p></def></def-item><def-item><term>IV</term><def><p>Intravenous</p></def></def-item><def-item><term>NMR</term><def><p>Nuclear magnetic resonance</p></def></def-item><def-item><term>NSAID</term><def><p>Nonsteroidal anti-inflammatory drug</p></def></def-item><def-item><term>PS</term><def><p>Presenilin</p></def></def-item><def-item><term>TLC</term><def><p>Thin-layer chromatography</p></def></def-item></def-list></glossary><fn-group><fn><p><bold>Competing interests</bold></p><p>The authors declare that they have no competing interests.</p></fn><fn><p><bold>Authors&#x02019; contributions</bold></p><p>IFL carried out the ELISAs, performed the statistical analysis and drafted the manuscript. TEG participated in the design of the study, provided reagents and advised on the manuscript. DRG conceived of the study and participated in its design and coordination, provided reagents and advised on the manuscript. EHK conceived the study and participated in its design and coordination, provided reagents, contributed to analysis and drafted the manuscript. All authors read and approved the final manuscript.</p></fn></fn-group><ack><title>Acknowledgements</title><p>We gratefully thank Hiroko Murayama and Helen Vanderswag for their technical assistance, Dr. Rema Raman for reviewing statistical analysis, and the University of California San Diego Shiley-Marcos Alzheimer&#x02019;s Disease Center for assistant in patient recruitment.</p><p>This study was supported by NIH AG 20206 (EHK, DRG, TEG) and AG 05131 (EHK, DRG).</p></ack><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McKhann</surname><given-names>GM</given-names></name><name><surname>Knopman</surname><given-names>DS</given-names></name><name><surname>Chertkow</surname><given-names>H</given-names></name><name><surname>Hyman</surname><given-names>BT</given-names></name><name><surname>Jack</surname><given-names>CR</given-names><suffix>Jr</suffix></name><name><surname>Kawas</surname><given-names>CH</given-names></name><etal/></person-group><article-title>The diagnosis of dementia due to Alzheimer&#x02019;s disease: recommendations from the National Institute on Aging-Alzheimer&#x02019;s Association workgroups on diagnostic guidelines for Alzheimer's disease</article-title><source>Alzheimers Dement</source><year>2011</year><volume>7</volume><fpage>263</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1016/j.jalz.2011.03.005</pub-id><pub-id pub-id-type="pmid">21514250</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Querfurth</surname><given-names>HW</given-names></name><name><surname>LaFerla</surname><given-names>FM</given-names></name></person-group><article-title>Alzheimer&#x02019;s disease</article-title><source>N Engl J Med</source><year>2010</year><volume>362</volume><fpage>329</fpage><lpage>44</lpage><pub-id pub-id-type="doi">10.1056/NEJMra0909142</pub-id><pub-id pub-id-type="pmid">20107219</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hardy</surname><given-names>J</given-names></name><name><surname>Selkoe</surname><given-names>DJ</given-names></name></person-group><article-title>The amyloid hypothesis of Alzheimer&#x02019;s disease: progress and problems on the road to therapeutics</article-title><source>Science</source><year>2002</year><volume>297</volume><fpage>353</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1126/science.1072994</pub-id><pub-id pub-id-type="pmid">12130773</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Karran</surname><given-names>E</given-names></name><name><surname>Mercken</surname><given-names>M</given-names></name><name><surname>De Strooper</surname><given-names>B</given-names></name></person-group><article-title>The amyloid cascade hypothesis for Alzheimer&#x02019;s disease: an appraisal for the development of therapeutics</article-title><source>Nat Rev Drug Discov</source><year>2011</year><volume>10</volume><fpage>698</fpage><lpage>712</lpage><pub-id pub-id-type="doi">10.1038/nrd3505</pub-id><pub-id pub-id-type="pmid">21852788</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thinakaran</surname><given-names>G</given-names></name><name><surname>Koo</surname><given-names>EH</given-names></name></person-group><article-title>Amyloid precursor protein trafficking, processing, and function</article-title><source>J Biol Chem</source><year>2008</year><volume>283</volume><fpage>29615</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1074/jbc.R800019200</pub-id><pub-id pub-id-type="pmid">18650430</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beher</surname><given-names>D</given-names></name><name><surname>Wrigley</surname><given-names>JD</given-names></name><name><surname>Owens</surname><given-names>AP</given-names></name><name><surname>Shearman</surname><given-names>MS</given-names></name></person-group><article-title>Generation of C-terminally truncated amyloid-beta peptides is dependent on gamma-secretase activity</article-title><source>J Neurochem</source><year>2002</year><volume>82</volume><fpage>563</fpage><lpage>75</lpage><pub-id pub-id-type="doi">10.1046/j.1471-4159.2002.00985.x</pub-id><pub-id pub-id-type="pmid">12153480</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jarrett</surname><given-names>JT</given-names></name><name><surname>Berger</surname><given-names>EP</given-names></name><name><surname>Lansbury</surname><given-names>PT</given-names><suffix>Jr</suffix></name></person-group><article-title>The carboxy terminus of the beta amyloid protein is critical for the seeding of amyloid formation: implications for the pathogenesis of Alzheimer&#x02019;s disease</article-title><source>Biochemistry</source><year>1993</year><volume>32</volume><fpage>4693</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1021/bi00069a001</pub-id><pub-id pub-id-type="pmid">8490014</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lambert</surname><given-names>MP</given-names></name><name><surname>Barlow</surname><given-names>AK</given-names></name><name><surname>Chromy</surname><given-names>BA</given-names></name><name><surname>Edwards</surname><given-names>C</given-names></name><name><surname>Freed</surname><given-names>R</given-names></name><name><surname>Liosatos</surname><given-names>M</given-names></name><etal/></person-group><article-title>Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins</article-title><source>Proc Natl Acad Sci U S A</source><year>1998</year><volume>95</volume><fpage>6448</fpage><lpage>53</lpage><pub-id pub-id-type="doi">10.1073/pnas.95.11.6448</pub-id><pub-id pub-id-type="pmid">9600986</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><mixed-citation publication-type="other">Tanzi RE. The genetics of Alzheimer disease. Cold Spring Harb Perspect Med. 2012;2. doi:10.1101/cshperspect.a006296.</mixed-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Citron</surname><given-names>M</given-names></name><name><surname>Westaway</surname><given-names>D</given-names></name><name><surname>Xia</surname><given-names>W</given-names></name><name><surname>Carlson</surname><given-names>G</given-names></name><name><surname>Diehl</surname><given-names>T</given-names></name><name><surname>Levesque</surname><given-names>G</given-names></name><etal/></person-group><article-title>Mutant presenilins of Alzheimer&#x02019;s disease increase production of 42-residue amyloid beta-protein in both transfected cells and transgenic mice</article-title><source>Nat Med</source><year>1997</year><volume>3</volume><fpage>67</fpage><lpage>72</lpage><pub-id pub-id-type="doi">10.1038/nm0197-67</pub-id><pub-id pub-id-type="pmid">8986743</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scheuner</surname><given-names>D</given-names></name><name><surname>Eckman</surname><given-names>C</given-names></name><name><surname>Jensen</surname><given-names>M</given-names></name><name><surname>Song</surname><given-names>X</given-names></name><name><surname>Citron</surname><given-names>M</given-names></name><name><surname>Suzuki</surname><given-names>N</given-names></name><etal/></person-group><article-title>Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer&#x02019;s disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer&#x02019;s disease</article-title><source>Nat Med</source><year>1996</year><volume>2</volume><fpage>864</fpage><lpage>70</lpage><pub-id pub-id-type="doi">10.1038/nm0896-864</pub-id><pub-id pub-id-type="pmid">8705854</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Howard</surname><given-names>R</given-names></name><name><surname>McShane</surname><given-names>R</given-names></name><name><surname>Lindesay</surname><given-names>J</given-names></name><name><surname>Ritchie</surname><given-names>C</given-names></name><name><surname>Baldwin</surname><given-names>A</given-names></name><name><surname>Barber</surname><given-names>R</given-names></name><etal/></person-group><article-title>Donepezil and memantine for moderate-to-severe Alzheimer&#x02019;s disease</article-title><source>N Engl J Med</source><year>2012</year><volume>366</volume><fpage>893</fpage><lpage>903</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1106668</pub-id><pub-id pub-id-type="pmid">22397651</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Golde</surname><given-names>TE</given-names></name><name><surname>Koo</surname><given-names>EH</given-names></name><name><surname>Felsenstein</surname><given-names>KM</given-names></name><name><surname>Osborne</surname><given-names>BA</given-names></name><name><surname>Miele</surname><given-names>L</given-names></name></person-group><article-title>Gamma-secretase inhibitors and modulators</article-title><source>Biochim Biophys Acta</source><year>1828</year><volume>2013</volume><fpage>2898</fpage><lpage>907</lpage></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wolfe</surname><given-names>MS</given-names></name></person-group><article-title>Gamma-secretase as a target for Alzheimer&#x02019;s disease</article-title><source>Adv Pharmacol</source><year>2012</year><volume>64</volume><fpage>127</fpage><lpage>53</lpage><pub-id pub-id-type="doi">10.1016/B978-0-12-394816-8.00004-0</pub-id><pub-id pub-id-type="pmid">22840746</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Okochi</surname><given-names>M</given-names></name><name><surname>Tagami</surname><given-names>S</given-names></name><name><surname>Yanagida</surname><given-names>K</given-names></name><name><surname>Takami</surname><given-names>M</given-names></name><name><surname>Kodama</surname><given-names>TS</given-names></name><name><surname>Mori</surname><given-names>K</given-names></name><etal/></person-group><article-title>Gamma-secretase modulators and presenilin 1 mutants act differently on presenilin/gamma-secretase function to cleave Abeta42 and Abeta43</article-title><source>Cell Rep</source><year>2013</year><volume>3</volume><fpage>42</fpage><lpage>51</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2012.11.028</pub-id><pub-id pub-id-type="pmid">23291095</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weggen</surname><given-names>S</given-names></name><name><surname>Eriksen</surname><given-names>JL</given-names></name><name><surname>Das</surname><given-names>P</given-names></name><name><surname>Sagi</surname><given-names>SA</given-names></name><name><surname>Wang</surname><given-names>R</given-names></name><name><surname>Pietrzik</surname><given-names>CU</given-names></name><etal/></person-group><article-title>A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity</article-title><source>Nature</source><year>2001</year><volume>414</volume><fpage>212</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1038/35102591</pub-id><pub-id pub-id-type="pmid">11700559</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McGeer</surname><given-names>PL</given-names></name><name><surname>McGeer</surname><given-names>EG</given-names></name></person-group><article-title>NSAIDs and Alzheimer disease: epidemiological, animal model and clinical studies</article-title><source>Neurobiol Aging</source><year>2007</year><volume>28</volume><fpage>639</fpage><lpage>47</lpage><pub-id pub-id-type="doi">10.1016/j.neurobiolaging.2006.03.013</pub-id><pub-id pub-id-type="pmid">16697488</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vlad</surname><given-names>SC</given-names></name><name><surname>Miller</surname><given-names>DR</given-names></name><name><surname>Kowall</surname><given-names>NW</given-names></name><name><surname>Felson</surname><given-names>DT</given-names></name></person-group><article-title>Protective effects of NSAIDs on the development of Alzheimer disease</article-title><source>Neurology</source><year>2008</year><volume>70</volume><fpage>1672</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1212/01.wnl.0000311269.57716.63</pub-id><pub-id pub-id-type="pmid">18458226</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><mixed-citation publication-type="other">Oehlrich D, Berthelot DJ, Gijsen HJ. Gamma-secretase modulators as potential disease modifying anti-alzheimer&#x02019;s drugs. J Med Chem. 2011. doi:10.1021/jm101168r.</mixed-citation></ref><ref id="CR20"><label>20.</label><mixed-citation publication-type="other">Golde TE, Koo EH, Felsenstein KM, Osborne BA, Miele L. Gamma-secretase inhibitors and modulators. Biochim Biophys Acta. 2013. doi:10.1016/j.bbamem.2013.06.005.</mixed-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bulic</surname><given-names>B</given-names></name><name><surname>Ness</surname><given-names>J</given-names></name><name><surname>Hahn</surname><given-names>S</given-names></name><name><surname>Rennhack</surname><given-names>A</given-names></name><name><surname>Jumpertz</surname><given-names>T</given-names></name><name><surname>Weggen</surname><given-names>S</given-names></name></person-group><article-title>Chemical biology, molecular mechanism and clinical perspective of gamma-secretase modulators in Alzheimer&#x02019;s disease</article-title><source>Curr Neuropharmacol</source><year>2011</year><volume>9</volume><fpage>598</fpage><lpage>622</lpage><pub-id pub-id-type="doi">10.2174/157015911798376352</pub-id><pub-id pub-id-type="pmid">22798753</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kukar</surname><given-names>T</given-names></name><name><surname>Prescott</surname><given-names>S</given-names></name><name><surname>Eriksen</surname><given-names>JL</given-names></name><name><surname>Holloway</surname><given-names>V</given-names></name><name><surname>Murphy</surname><given-names>MP</given-names></name><name><surname>Koo</surname><given-names>EH</given-names></name><etal/></person-group><article-title>Chronic administration of R-flurbiprofen attenuates learning impairments in transgenic amyloid precursor protein mice</article-title><source>BMC Neurosci</source><year>2007</year><volume>8</volume><fpage>54</fpage><pub-id pub-id-type="doi">10.1186/1471-2202-8-54</pub-id><pub-id pub-id-type="pmid">17650315</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Green</surname><given-names>RC</given-names></name><name><surname>Schneider</surname><given-names>LS</given-names></name><name><surname>Amato</surname><given-names>DA</given-names></name><name><surname>Beelen</surname><given-names>AP</given-names></name><name><surname>Wilcock</surname><given-names>G</given-names></name><name><surname>Swabb</surname><given-names>EA</given-names></name><etal/></person-group><article-title>Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: a randomized controlled trial</article-title><source>JAMA</source><year>2009</year><volume>302</volume><fpage>2557</fpage><lpage>64</lpage><pub-id pub-id-type="doi">10.1001/jama.2009.1866</pub-id><pub-id pub-id-type="pmid">20009055</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McKee</surname><given-names>AC</given-names></name><name><surname>Carreras</surname><given-names>I</given-names></name><name><surname>Hossain</surname><given-names>L</given-names></name><name><surname>Ryu</surname><given-names>H</given-names></name><name><surname>Klein</surname><given-names>WL</given-names></name><name><surname>Oddo</surname><given-names>S</given-names></name><etal/></person-group><article-title>Ibuprofen reduces Abeta, hyperphosphorylated tau and memory deficits in Alzheimer mice</article-title><source>Brain Res</source><year>2008</year><volume>1207</volume><fpage>225</fpage><lpage>36</lpage><pub-id pub-id-type="doi">10.1016/j.brainres.2008.01.095</pub-id><pub-id pub-id-type="pmid">18374906</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><mixed-citation publication-type="other">In t&#x02019; Veld BA, Ruitenberg A, Hofman A, Launer LJ, van Duijn CM, Stijnen T, et al. Nonsteroidal antiinflammatory drugs and the risk of Alzheimer&#x02019;s disease. N Engl J Med. 2001;345:1515&#x02013;21.</mixed-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lim</surname><given-names>GP</given-names></name><name><surname>Yang</surname><given-names>F</given-names></name><name><surname>Chu</surname><given-names>T</given-names></name><name><surname>Chen</surname><given-names>P</given-names></name><name><surname>Beech</surname><given-names>W</given-names></name><name><surname>Teter</surname><given-names>B</given-names></name><etal/></person-group><article-title>Ibuprofen suppresses plaque pathology and inflammation in a mouse model for Alzheimer&#x02019;s disease</article-title><source>J Neurosci</source><year>2000</year><volume>20</volume><fpage>5709</fpage><lpage>14</lpage><pub-id pub-id-type="pmid">10908610</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jantzen</surname><given-names>PT</given-names></name><name><surname>Connor</surname><given-names>KE</given-names></name><name><surname>DiCarlo</surname><given-names>G</given-names></name><name><surname>Wenk</surname><given-names>GL</given-names></name><name><surname>Wallace</surname><given-names>JL</given-names></name><name><surname>Rojiani</surname><given-names>AM</given-names></name><etal/></person-group><article-title>Microglial activation and beta -amyloid deposit reduction caused by a nitric oxide-releasing nonsteroidal anti-inflammatory drug in amyloid precursor protein plus presenilin-1 transgenic mice</article-title><source>J Neurosci</source><year>2002</year><volume>22</volume><fpage>2246</fpage><lpage>54</lpage><pub-id pub-id-type="pmid">11896164</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Page</surname><given-names>RM</given-names></name><name><surname>Baumann</surname><given-names>K</given-names></name><name><surname>Tomioka</surname><given-names>M</given-names></name><name><surname>Perez-Revuelta</surname><given-names>BI</given-names></name><name><surname>Fukumori</surname><given-names>A</given-names></name><name><surname>Jacobsen</surname><given-names>H</given-names></name><etal/></person-group><article-title>Generation of Abeta38 and Abeta42 is independently and differentially affected by familial Alzheimer disease-associated presenilin mutations and gamma-secretase modulation</article-title><source>J Biol Chem</source><year>2008</year><volume>283</volume><fpage>677</fpage><lpage>83</lpage><pub-id pub-id-type="doi">10.1074/jbc.M708754200</pub-id><pub-id pub-id-type="pmid">17962197</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cook</surname><given-names>JJ</given-names></name><name><surname>Wildsmith</surname><given-names>KR</given-names></name><name><surname>Gilberto</surname><given-names>DB</given-names></name><name><surname>Holahan</surname><given-names>MA</given-names></name><name><surname>Kinney</surname><given-names>GG</given-names></name><name><surname>Mathers</surname><given-names>PD</given-names></name><etal/></person-group><article-title>Acute gamma-secretase inhibition of nonhuman primate CNS shifts amyloid precursor protein (APP) metabolism from amyloid-beta production to alternative APP fragments without amyloid-beta rebound</article-title><source>J Neurosci</source><year>2010</year><volume>30</volume><fpage>6743</fpage><lpage>50</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.1381-10.2010</pub-id><pub-id pub-id-type="pmid">20463236</pub-id></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Hannam</surname><given-names>JC</given-names></name><name><surname>Kulagowski</surname><given-names>JJ</given-names></name><name><surname>Madin</surname><given-names>A</given-names></name><name><surname>Ridgill</surname><given-names>MP</given-names></name><name><surname>Seward</surname><given-names>EM</given-names></name></person-group><source>Piperidines and related compounds for treatment of Alzheimer&#x02019;s disease. International Patent W02006/043064</source><year>2006</year><publisher-loc>&#x00115;</publisher-loc><publisher-name>&#x00115;</publisher-name></element-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ran</surname><given-names>Y</given-names></name><name><surname>Cruz</surname><given-names>PE</given-names></name><name><surname>Ladd</surname><given-names>TB</given-names></name><name><surname>Fauq</surname><given-names>AH</given-names></name><name><surname>Jung</surname><given-names>JI</given-names></name><name><surname>Matthews</surname><given-names>J</given-names></name><etal/></person-group><article-title>Gamma-secretase processing and effects of gamma-secretase inhibitors and modulators on long Abeta peptides in cells</article-title><source>J Biol Chem</source><year>2014</year><volume>289</volume><fpage>3276</fpage><lpage>87</lpage><pub-id pub-id-type="doi">10.1074/jbc.M113.512921</pub-id><pub-id pub-id-type="pmid">24352661</pub-id></element-citation></ref><ref id="CR32"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jung</surname><given-names>JI</given-names></name><name><surname>Ran</surname><given-names>Y</given-names></name><name><surname>Cruz</surname><given-names>PE</given-names></name><name><surname>Rosario</surname><given-names>AM</given-names></name><name><surname>Ladd</surname><given-names>TB</given-names></name><name><surname>Kukar</surname><given-names>TL</given-names></name><etal/></person-group><article-title>Complex relationships between substrate sequence and sensitivity to alterations in gamma-secretase processivity induced by gamma-secretase modulators</article-title><source>Biochemistry</source><year>2014</year><volume>53</volume><fpage>1947</fpage><lpage>57</lpage><pub-id pub-id-type="doi">10.1021/bi401521t</pub-id><pub-id pub-id-type="pmid">24620716</pub-id></element-citation></ref><ref id="CR33"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gilberto</surname><given-names>DB</given-names></name><name><surname>Zeoli</surname><given-names>AH</given-names></name><name><surname>Szczerba</surname><given-names>PJ</given-names></name><name><surname>Gehret</surname><given-names>JR</given-names></name><name><surname>Holahan</surname><given-names>MA</given-names></name><name><surname>Sitko</surname><given-names>GR</given-names></name><etal/></person-group><article-title>An alternative method of chronic cerebrospinal fluid collection via the cisterna magna in conscious rhesus monkeys</article-title><source>Contemp Top Lab Anim Sci</source><year>2003</year><volume>42</volume><fpage>53</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">12906404</pub-id></element-citation></ref><ref id="CR34"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Levites</surname><given-names>Y</given-names></name><name><surname>Das</surname><given-names>P</given-names></name><name><surname>Price</surname><given-names>RW</given-names></name><name><surname>Rochette</surname><given-names>MJ</given-names></name><name><surname>Kostura</surname><given-names>LA</given-names></name><name><surname>McGowan</surname><given-names>EM</given-names></name><etal/></person-group><article-title>Anti-Abeta42- and anti-Abeta40-specific mAbs attenuate amyloid deposition in an Alzheimer disease mouse model</article-title><source>J Clin Invest</source><year>2006</year><volume>116</volume><fpage>193</fpage><lpage>201</lpage><pub-id pub-id-type="doi">10.1172/JCI25410</pub-id><pub-id pub-id-type="pmid">16341263</pub-id></element-citation></ref><ref id="CR35"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bateman</surname><given-names>RJ</given-names></name><name><surname>Wen</surname><given-names>G</given-names></name><name><surname>Morris</surname><given-names>JC</given-names></name><name><surname>Holtzman</surname><given-names>DM</given-names></name></person-group><article-title>Fluctuations of CSF amyloid-beta levels: implications for a diagnostic and therapeutic biomarker</article-title><source>Neurology</source><year>2007</year><volume>68</volume><fpage>666</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1212/01.wnl.0000256043.50901.e3</pub-id><pub-id pub-id-type="pmid">17325273</pub-id></element-citation></ref><ref id="CR36"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Siemers</surname><given-names>ER</given-names></name><name><surname>Dean</surname><given-names>RA</given-names></name><name><surname>Friedrich</surname><given-names>S</given-names></name><name><surname>Ferguson-Sells</surname><given-names>L</given-names></name><name><surname>Gonzales</surname><given-names>C</given-names></name><name><surname>Farlow</surname><given-names>MR</given-names></name><etal/></person-group><article-title>Safety, tolerability, and effects on plasma and cerebrospinal fluid amyloid-beta after inhibition of gamma-secretase</article-title><source>Clin Neuropharmacol</source><year>2007</year><volume>30</volume><fpage>317</fpage><lpage>25</lpage><pub-id pub-id-type="doi">10.1097/WNF.0b013e31805b7660</pub-id><pub-id pub-id-type="pmid">18090456</pub-id></element-citation></ref><ref id="CR37"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pavliv</surname><given-names>L</given-names></name><name><surname>Voss</surname><given-names>B</given-names></name><name><surname>Rock</surname><given-names>A</given-names></name></person-group><article-title>Pharmacokinetics, safety, and tolerability of a rapid infusion of i.v. ibuprofen in healthy adults</article-title><source>Am J Health Syst Pharm</source><year>2011</year><volume>68</volume><fpage>47</fpage><lpage>51</lpage><pub-id pub-id-type="doi">10.2146/ajhp100120</pub-id><pub-id pub-id-type="pmid">21164065</pub-id></element-citation></ref><ref id="CR38"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Evans</surname><given-names>AM</given-names></name><name><surname>Nation</surname><given-names>RL</given-names></name><name><surname>Sansom</surname><given-names>LN</given-names></name><name><surname>Bochner</surname><given-names>F</given-names></name><name><surname>Somogyi</surname><given-names>AA</given-names></name></person-group><article-title>Stereoselective plasma protein binding of ibuprofen enantiomers</article-title><source>Eur J Clin Pharmacol</source><year>1989</year><volume>36</volume><fpage>283</fpage><lpage>90</lpage><pub-id pub-id-type="doi">10.1007/BF00558161</pub-id><pub-id pub-id-type="pmid">2744069</pub-id></element-citation></ref><ref id="CR39"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Galasko</surname><given-names>DR</given-names></name><name><surname>Graff-Radford</surname><given-names>N</given-names></name><name><surname>May</surname><given-names>S</given-names></name><name><surname>Hendrix</surname><given-names>S</given-names></name><name><surname>Cottrell</surname><given-names>BA</given-names></name><name><surname>Sagi</surname><given-names>SA</given-names></name><etal/></person-group><article-title>Safety, tolerability, pharmacokinetics, and Abeta levels after short-term administration of R-flurbiprofen in healthy elderly individuals</article-title><source>Alzheimer Dis Assoc Disord</source><year>2007</year><volume>21</volume><fpage>292</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1097/WAD.0b013e31815d1048</pub-id><pub-id pub-id-type="pmid">18090435</pub-id></element-citation></ref><ref id="CR40"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hucker</surname><given-names>HB</given-names></name><name><surname>Zacchei</surname><given-names>AG</given-names></name><name><surname>Cox</surname><given-names>SV</given-names></name><name><surname>Brodie</surname><given-names>DA</given-names></name><name><surname>Cantwell</surname><given-names>NHR</given-names></name></person-group><article-title>Studies on the absorption, distribution and excretion of indomethacin in various species</article-title><source>J Pharm Exp Ther</source><year>1966</year><volume>153</volume><fpage>237</fpage><lpage>49</lpage></element-citation></ref><ref id="CR41"><label>41.</label><mixed-citation publication-type="other">Barnes JN, Charkoudian N, Matzek LJ, Johnson CP, Joyner MJ, Curry TB. Acute cyclooxygenase inhibition does not alter muscle sympathetic nerve activity or forearm vasodilator responsiveness in lean and obese adults. Physiol Rep. 2014;2. doi:10.14814/phy2.12079.</mixed-citation></ref><ref id="CR42"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Imbimbo</surname><given-names>BP</given-names></name></person-group><article-title>An update on the efficacy of non-steroidal anti-inflammatory drugs in Alzheimer&#x02019;s disease</article-title><source>Expert Opin Investig Drugs</source><year>2009</year><volume>18</volume><fpage>1147</fpage><lpage>68</lpage><pub-id pub-id-type="doi">10.1517/13543780903066780</pub-id><pub-id pub-id-type="pmid">19589092</pub-id></element-citation></ref><ref id="CR43"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Szekely</surname><given-names>CA</given-names></name><name><surname>Green</surname><given-names>RC</given-names></name><name><surname>Breitner</surname><given-names>JC</given-names></name><name><surname>Ostbye</surname><given-names>T</given-names></name><name><surname>Beiser</surname><given-names>AS</given-names></name><name><surname>Corrada</surname><given-names>MM</given-names></name><etal/></person-group><article-title>No advantage of A beta 42-lowering NSAIDs for prevention of Alzheimer dementia in six pooled cohort studies</article-title><source>Neurology</source><year>2008</year><volume>70</volume><fpage>2291</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1212/01.wnl.0000313933.17796.f6</pub-id><pub-id pub-id-type="pmid">18509093</pub-id></element-citation></ref><ref id="CR44"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pasqualetti</surname><given-names>P</given-names></name><name><surname>Bonomini</surname><given-names>C</given-names></name><name><surname>Dal Forno</surname><given-names>G</given-names></name><name><surname>Paulon</surname><given-names>L</given-names></name><name><surname>Sinforiani</surname><given-names>E</given-names></name><name><surname>Marra</surname><given-names>C</given-names></name><etal/></person-group><article-title>A randomized controlled study on effects of ibuprofen on cognitive progression of Alzheimer&#x02019;s disease</article-title><source>Aging Clin Exp Res</source><year>2009</year><volume>21</volume><fpage>102</fpage><lpage>10</lpage><pub-id pub-id-type="doi">10.1007/BF03325217</pub-id><pub-id pub-id-type="pmid">19448381</pub-id></element-citation></ref><ref id="CR45"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aisen</surname><given-names>PS</given-names></name><name><surname>Schafer</surname><given-names>KA</given-names></name><name><surname>Grundman</surname><given-names>M</given-names></name><name><surname>Pfeiffer</surname><given-names>E</given-names></name><name><surname>Sano</surname><given-names>M</given-names></name><name><surname>Davis</surname><given-names>KL</given-names></name><etal/></person-group><article-title>Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial</article-title><source>JAMA</source><year>2003</year><volume>289</volume><fpage>2819</fpage><lpage>26</lpage><pub-id pub-id-type="doi">10.1001/jama.289.21.2819</pub-id><pub-id pub-id-type="pmid">12783912</pub-id></element-citation></ref><ref id="CR46"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scharf</surname><given-names>S</given-names></name><name><surname>Mander</surname><given-names>A</given-names></name><name><surname>Ugoni</surname><given-names>A</given-names></name><name><surname>Vajda</surname><given-names>F</given-names></name><name><surname>Christophidis</surname><given-names>N</given-names></name></person-group><article-title>A double-blind, placebo-controlled trial of diclofenac/misoprostol in Alzheimer&#x02019;s disease</article-title><source>Neurology</source><year>1999</year><volume>53</volume><fpage>197</fpage><lpage>201</lpage><pub-id pub-id-type="doi">10.1212/WNL.53.1.197</pub-id><pub-id pub-id-type="pmid">10408559</pub-id></element-citation></ref><ref id="CR47"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thal</surname><given-names>LJ</given-names></name><name><surname>Ferris</surname><given-names>SH</given-names></name><name><surname>Kirby</surname><given-names>L</given-names></name><name><surname>Block</surname><given-names>GA</given-names></name><name><surname>Lines</surname><given-names>CR</given-names></name><name><surname>Yuen</surname><given-names>E</given-names></name><etal/></person-group><article-title>A randomized, double-blind, study of rofecoxib in patients with mild cognitive impairment</article-title><source>Neuropsychopharmacology</source><year>2005</year><volume>30</volume><fpage>1204</fpage><lpage>15</lpage><pub-id pub-id-type="doi">10.1038/sj.npp.1300690</pub-id><pub-id pub-id-type="pmid">15742005</pub-id></element-citation></ref><ref id="CR48"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reines</surname><given-names>SA</given-names></name><name><surname>Block</surname><given-names>GA</given-names></name><name><surname>Morris</surname><given-names>JC</given-names></name><name><surname>Liu</surname><given-names>G</given-names></name><name><surname>Nessly</surname><given-names>ML</given-names></name><name><surname>Lines</surname><given-names>CR</given-names></name><etal/></person-group><article-title>Rofecoxib: no effect on Alzheimer&#x02019;s disease in a 1-year, randomized, blinded, controlled study</article-title><source>Neurology</source><year>2004</year><volume>62</volume><fpage>66</fpage><lpage>71</lpage><pub-id pub-id-type="doi">10.1212/WNL.62.1.66</pub-id><pub-id pub-id-type="pmid">14718699</pub-id></element-citation></ref><ref id="CR49"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Szekely</surname><given-names>CA</given-names></name><name><surname>Zandi</surname><given-names>PP</given-names></name></person-group><article-title>Non-steroidal anti-inflammatory drugs and Alzheimer&#x02019;s disease: the epidemiological evidence</article-title><source>CNS Neurol Disord Drug Targets</source><year>2010</year><volume>9</volume><fpage>132</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.2174/187152710791012026</pub-id><pub-id pub-id-type="pmid">20205647</pub-id></element-citation></ref><ref id="CR50"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cole</surname><given-names>GM</given-names></name><name><surname>Frautschy</surname><given-names>SA</given-names></name></person-group><article-title>Mechanisms of action of non-steroidal anti-inflammatory drugs for the prevention of Alzheimer&#x02019;s disease</article-title><source>CNS Neurol Disord Drug Targets</source><year>2010</year><volume>9</volume><fpage>140</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.2174/187152710791011991</pub-id><pub-id pub-id-type="pmid">20205646</pub-id></element-citation></ref><ref id="CR51"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eriksen</surname><given-names>JL</given-names></name><name><surname>Sagi</surname><given-names>SA</given-names></name><name><surname>Smith</surname><given-names>TE</given-names></name><name><surname>Weggen</surname><given-names>S</given-names></name><name><surname>Das</surname><given-names>P</given-names></name><name><surname>McLendon</surname><given-names>DC</given-names></name><etal/></person-group><article-title>NSAIDs and enantiomers of flurbiprofen target gamma-secretase and lower Abeta 42 in vivo</article-title><source>J Clin Invest</source><year>2003</year><volume>112</volume><fpage>440</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1172/JCI18162</pub-id><pub-id pub-id-type="pmid">12897211</pub-id></element-citation></ref><ref id="CR52"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shah</surname><given-names>A</given-names></name><name><surname>Jung</surname><given-names>D</given-names></name></person-group><article-title>Dose-dependent pharmacokinetics of ibuprofen in the rat</article-title><source>Drug Metab Dispos</source><year>1987</year><volume>15</volume><fpage>151</fpage><lpage>4</lpage><pub-id pub-id-type="pmid">2882970</pub-id></element-citation></ref><ref id="CR53"><label>53.</label><mixed-citation publication-type="other">Hillmann A, Hahn S, Schilling S, Hoffmann T, Demuth HU, Bulic B, et al. No improvement after chronic ibuprofen treatment in the 5XFAD mouse model of Alzheimer&#x02019;s disease. Neurobiol Aging. 2012;33:833 e39&#x02013;50.</mixed-citation></ref><ref id="CR54"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Czirr</surname><given-names>E</given-names></name><name><surname>Cottrell</surname><given-names>BA</given-names></name><name><surname>Leuchtenberger</surname><given-names>S</given-names></name><name><surname>Kukar</surname><given-names>T</given-names></name><name><surname>Ladd</surname><given-names>TB</given-names></name><name><surname>Esselmann</surname><given-names>H</given-names></name><etal/></person-group><article-title>Independent generation of Abeta42 and Abeta38 peptide species by gamma-secretase</article-title><source>J Biol Chem</source><year>2008</year><volume>283</volume><fpage>17049</fpage><lpage>54</lpage><pub-id pub-id-type="doi">10.1074/jbc.M802912200</pub-id><pub-id pub-id-type="pmid">18426795</pub-id></element-citation></ref><ref id="CR55"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Loureiro</surname><given-names>RM</given-names></name><name><surname>Dumin</surname><given-names>JA</given-names></name><name><surname>McKee</surname><given-names>TD</given-names></name><name><surname>Austin</surname><given-names>WF</given-names></name><name><surname>Fuller</surname><given-names>NO</given-names></name><name><surname>Hubbs</surname><given-names>JL</given-names></name><etal/></person-group><article-title>Efficacy of SPI-1865, a novel gamma-secretase modulator, in multiple rodent models</article-title><source>Alzheimers Res Ther</source><year>2013</year><volume>5</volume><fpage>19</fpage><pub-id pub-id-type="doi">10.1186/alzrt173</pub-id><pub-id pub-id-type="pmid">23597079</pub-id></element-citation></ref><ref id="CR56"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hussain</surname><given-names>I</given-names></name><name><surname>Harrison</surname><given-names>DC</given-names></name><name><surname>Hawkins</surname><given-names>J</given-names></name><name><surname>Chapman</surname><given-names>T</given-names></name><name><surname>Marshall</surname><given-names>I</given-names></name><name><surname>Facci</surname><given-names>L</given-names></name><etal/></person-group><article-title>TASTPM mice expressing amyloid precursor protein and presenilin-1 mutant transgenes are sensitive to gamma-secretase modulation and amyloid-beta(4)(2) lowering by GSM-10h</article-title><source>Neurodegener Dis</source><year>2011</year><volume>8</volume><fpage>15</fpage><lpage>24</lpage><pub-id pub-id-type="doi">10.1159/000313903</pub-id><pub-id pub-id-type="pmid">20689247</pub-id></element-citation></ref><ref id="CR57"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kukar</surname><given-names>TL</given-names></name><name><surname>Ladd</surname><given-names>TB</given-names></name><name><surname>Bann</surname><given-names>MA</given-names></name><name><surname>Fraering</surname><given-names>PC</given-names></name><name><surname>Narlawar</surname><given-names>R</given-names></name><name><surname>Maharvi</surname><given-names>GM</given-names></name><etal/></person-group><article-title>Substrate-targeting gamma-secretase modulators</article-title><source>Nature</source><year>2008</year><volume>453</volume><fpage>925</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1038/nature07055</pub-id><pub-id pub-id-type="pmid">18548070</pub-id></element-citation></ref><ref id="CR58"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Crump</surname><given-names>CJ</given-names></name><name><surname>Fish</surname><given-names>BA</given-names></name><name><surname>Castro</surname><given-names>SV</given-names></name><name><surname>Chau</surname><given-names>DM</given-names></name><name><surname>Gertsik</surname><given-names>N</given-names></name><name><surname>Ahn</surname><given-names>K</given-names></name><etal/></person-group><article-title>Piperidine acetic acid based gamma-secretase modulators directly bind to Presenilin-1</article-title><source>ACS Chem Neurosci</source><year>2011</year><volume>2</volume><fpage>705</fpage><lpage>10</lpage><pub-id pub-id-type="doi">10.1021/cn200098p</pub-id><pub-id pub-id-type="pmid">22229075</pub-id></element-citation></ref><ref id="CR59"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ohki</surname><given-names>Y</given-names></name><name><surname>Higo</surname><given-names>T</given-names></name><name><surname>Uemura</surname><given-names>K</given-names></name><name><surname>Shimada</surname><given-names>N</given-names></name><name><surname>Osawa</surname><given-names>S</given-names></name><name><surname>Berezovska</surname><given-names>O</given-names></name><etal/></person-group><article-title>Phenylpiperidine-type gamma-secretase modulators target the transmembrane domain 1 of presenilin 1</article-title><source>EMBO J</source><year>2011</year><volume>30</volume><fpage>4815</fpage><lpage>24</lpage><pub-id pub-id-type="doi">10.1038/emboj.2011.372</pub-id><pub-id pub-id-type="pmid">22002539</pub-id></element-citation></ref><ref id="CR60"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jumpertz</surname><given-names>T</given-names></name><name><surname>Rennhack</surname><given-names>A</given-names></name><name><surname>Ness</surname><given-names>J</given-names></name><name><surname>Baches</surname><given-names>S</given-names></name><name><surname>Pietrzik</surname><given-names>CU</given-names></name><name><surname>Bulic</surname><given-names>B</given-names></name><etal/></person-group><article-title>Presenilin is the molecular target of acidic gamma-secretase modulators in living cells</article-title><source>PLoS One</source><year>2012</year><volume>7</volume><pub-id pub-id-type="doi">10.1371/journal.pone.0030484</pub-id><pub-id pub-id-type="pmid">22238696</pub-id></element-citation></ref><ref id="CR61"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pozdnyakov</surname><given-names>N</given-names></name><name><surname>Murrey</surname><given-names>HE</given-names></name><name><surname>Crump</surname><given-names>CJ</given-names></name><name><surname>Pettersson</surname><given-names>M</given-names></name><name><surname>Ballard</surname><given-names>TE</given-names></name><name><surname>Am Ende</surname><given-names>CW</given-names></name><etal/></person-group><article-title>Gamma-secretase modulator (GSM) photoaffinity probes reveal distinct allosteric binding sites on presenilin</article-title><source>J Biol Chem</source><year>2013</year><volume>288</volume><fpage>9710</fpage><lpage>20</lpage><pub-id pub-id-type="doi">10.1074/jbc.M112.398602</pub-id><pub-id pub-id-type="pmid">23396974</pub-id></element-citation></ref></ref-list></back></article>